2. Signaling Pathways
  3. Stem Cell/Wnt
  4. β-catenin
  5. β-catenin Antagonist

β-catenin Antagonist

β-catenin Antagonists (5):

Cat. No. Product Name Effect Purity
  • HY-P10392B
    aStAx-35R TFA
    		Antagonist 98.43%
    aStAx-35R TFA, a stapled peptide, antagonizes nuclear form of β-catenin and inhibits Wnt signaling. aStAx-35R TFA inhibits competitively the binding of β-catenin to TCF4. aStAx-35R TFA selectively induces growth inhibition of Wnt-dependent cancer cells.
  • HY-101486
    LF3
    		Antagonist 99.55%
    LF3 is an antagonist of the β-Catenin/TCF4 interaction with antitumor activity; has an IC50 of 1.65 μM.
  • HY-109103
    Tegatrabetan
    		Antagonist 99.77%
    Tegatrabetan (BC2059) is a β-Catenin antagonist. Tegatrabetan disrupts the binding of β-catenin with the scaffold protein transducin β-like 1 (TBL1).
  • HY-N7702
    N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide
    		Antagonist 99.48%
    N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide is a macamide isolated from Maca (Lepidium meyenii Walp.) N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide induces mesenchymal stem cells osteogenic differentiation and consequent bone formation through activating the canonical Wnt/β‐catenin signaling pathway. N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide can be used for the research of osteoporosis.
  • HY-P10392
    aStAx-35R
    		Antagonist
    aStAx-35R, a stapled peptide, antagonizes nuclear form of β-catenin and inhibits Wnt signaling. aStAx-35R inhibits competitively the binding of β-catenin to TCF4. aStAx-35R selectively induces growth inhibition of Wnt-dependent cancer cells.